The physical health challenges in patients with severe mental illness: cardiovascular and metabolic risks

Abstract

This supplement is the output of a roundtable discussion, attended by a multidisciplinary panel with a broad range of expertise, which includes the treatment of severe mental illness, cardiovascular disease, diabetes and pharmaceutical prescribing.

The roundtable and writing of the supplement were organised and paid for by MSD, including the payment of Steve Titmarsh, a medical writer who was involved in the preparation and editing of this document

Get full access to this article

View all access options for this article.

References

Alberti G.

Zimmet P.

Shaw J.

and

Grundy SM

( 2005) International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. Brussels : IDF2005.

Allison DB

Mentore JL

Heo M.

, et al. (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry156: 1686-1696.

Arranz B.

Rosel P.

Ramrez N.

, et al. (2004) Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. J Clin Psychiatry65: 1335-1342.

Assmann G.

Schulte H.

Cullen P.

and

Seedorf U.

( 2007) Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Münster (PROCAM) study. Eur J Clin Invest37: 925-932.

Barnes TRE

Paton C.

Hancock E.

, et al. (2008) Screening for metabolic syndrome in community psychiatric patients prescribed antipsychotics: a quality improvement programme . Acta Psychiatr Scand118: 26-33.

Barnett AH

Mackin P.

Chaudhry I.

, et al. (2007) Minimising cardiovascular and metabolic risk in schizophrenia; diabetes, obesity and dyslipidaemia. J Psychopharmacol21: 357-373.

Bennett

et al. (1994) Side Effect Scale/Checlist for Antipsychotic Medication (SESCAM). Available at: http://www.schizophrenia-guidelines.co.uk/resources/Resources/SESCAM.pdf

Brown S.

( 1997) Excess mortality of schizophrenia. A meta-analysis . Br J Psych171: 502-508.

Chagnon YC

( 2006) Susceptibility genes for the side effect of antipsychotics on body weight and obesity. Curr Drug Targets7: 1681-1695.

10.

Citrome LL

Holt RI

Zachry WM

, et al. (2007) Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics. Ann Pharmacother41: 1593-1603.

11.

Colditz GA

Willett WC

Rotnitzky A.

and

Manson JE

( 1995) Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med122: 481-486.

12.

De Hert M.

Scheurs V.

, Vancampfort D and van Winkel R (2009) Metabolic syndrome in people with schizophrenia: a review. World Psychiatry8: 15-22.

13.

Department of Health

(2006) Choosing Health: Supporting the physical health needs of people with severe mental illness - Commissioning Frameworkwww.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4138212 (accessed 26 April 2010).

14.

Dickerson FB

Brown CH

Kreyenbuhl JA

, et al. (2006) Obesity among individuals with serious mental illness. Acta Psychiatr Scand113: 306-313.

15.

Fagiolini A.

Frank E.

Scott JA

Turkin S.

and

Kupfer DJ

( 2005) Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord7: 424-430.

16.

Flegal KM

Carroll MD

, Ogden CL and Curtin LR (2010) Prevalence and trends in obesity among US adults, 1999-2008. JAMA303: 235-241.

17.

Hogan TP

Awad AG

and

Eastwood R.

( 1983) A self-report scale predictive of drug compliance in schizophrenia: reliability and discriminative validity. Psychol Med13: 177-183.

18.

Holt RIG

and

Peveler RC

( 2006) Association between antipsychotic drugs and diabetes . Diab Obes Metab8: 125-135.

19.

Holt RIG

and

Peveler RC

( 2009) Obesity, serious mental illness and antipsychotic drugs . Diab Obes Metab11: 665-679.

20.

JBS2

(2005) Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice. Heart91(suppl 5): v1-52.

21.

Kinon BJ

Kaiser CJ

Ahmed S.

Rotelli MD

and

Kollack-Walker S.

( 2005) Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacol25: 255-258.

22.

Knowler WC

Barrett-Connor E.

Fowler SE

, et al. (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med346: 393-403.

23.

Maudsley H.

( 1868) The physiology and pathology of mind, 2nd edn. London: Macmillan .

24.

McEvoy JP

Meyer JM

Goff DC

, et al. (2005) Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res80: 19-32.

25.

Millar H.

( 2010) Screening in people with severe mental illness . Unpublished raw data.

26.

Millar HL

( 2010) Physical health in patients with schizophrenia: current knowledge and practice recommendations paper within entitled Development of a Health Screening Clinic. Eur Psychiat, Supplement. (in press).

27.

Ncep

(2001) Executive Summary of the Third Report of the National Cholesterol Executive Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. JAMA285: 2486-2497.

28.

Newcomer JW

and

Hennekens CH

( 2007) Severe mental illness and risk of cardiovascular disease . JAMA298: 1794-1796.

29.

NICE, National Institutes of Health and Clinical Excellence

(2006) Borderline personality disorder: Treatment and management (Clinical Guideline78).

30.

NICE, National Institute of Health and Clinical Excellence

( 2009) Schizophrenia: Core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. (Clinical Guideline82).

31.

Reynolds GP

( 2007) The impact of pharmacogenetics on the development and use of antipsychotic drugs. Drug Discov Today12: 953-959.

32.

Reynolds GP

and

Kirk S.

(2010) Metabolic side effects of antipsychotic drug treatment - pharmacological mechanisms. Pharmacol Ther125(1): 169-179.

33.

Sernyak MJ

Leslie DL

Alarcon RD

Losonczy MF

and

Rosenheck R.

( 2002) Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry159: 561-566.

34.

Taylor D.

Shapland L.

Laverick G.

, et al. (2000) Clozapine - a survey of patient perceptions . Psychiatr Bull R Coll Psychiatr24: 450-452.

35.

Taylor DM

Young C.

Esop R.

Paton C.

and

Walwyn R.

( 2004) Testing for diabetes in hospitalised patients prescribed antipsychotic drugs. Br J Psychiatry185: 152-156.

36.

Taylor D.

Young C.

Mohamed R.

Paton C.

and

Walwyn R.

( 2005) Undiagnosed impaired fasting glucose and diabetes mellitus amongst inpatients receiving antipsychotic drugs. J Psychopharmacol19: 182-186.

37.

Templeman LA

Reynolds GP

Arranz B.

and

San L.

( 2005) Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet Genomics15: 195-200.

38.

Thakore JH

Mann JN

Vlahos I.

Martin A.

and

Reznek R.

( 2002) Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord26: 137-141.

39.

Thonnard-Neumann E.

( 1968) Phenothiazines and diabetes in hospitalized women . Am J Psychiatry124: 978-982.

40.

Tiihonen J.

Lönnqvist J.

Wahlbeck K.

, et al. (2009) 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet374: 620-627

41.

Venables D.

Hughes J.

Stewart K.

and

Challis D.

( 2005) Variations in care management arrangements for people with mental health problems in England. Care Manag J6: 131-138.

42.

Weiden PJ

Mackell JA

and

Mcdonnell DD

( 2004) Obesity as a risk factor for antipsychotic noncompliance . Schizophr Res66: 51-57.

43.

Will J.

Galuska D.

Ford E.

Mokdad A.

and

Calle E.

( 2001). Cigarette smoking and diabetes mellitus: evidence of a positive association from a large prospective cohort study. Int J Epidemiol30: 540-546.

44.

World Health Organization. Available at: http://whqlibdoc.who.int/hq/1999/WHO_NCD_NCS_99.2.pdf

45.

Yevtushenko OO

Cooper SJ

O’Neill R.

Doherty JK

Woodside JV

and

Reynolds GP

( 2008) Influence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia . Br J Psychiatry192: 424-428.

46.

Zhang ZJ

Yao ZJ

Liu W.

Fang Q.

and

Reynolds GP

( 2004) Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry184: 58-62.